Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab rezetecan + retlirafusp alfa + CAPOX
- Development stage
- Phase 2
- Lead developer
- Jiangsu HengRui Medicine Co., Ltd.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Trastuzumab rezetecan + retlirafusp alfa + CAPOX is an investigational combination regimen being evaluated for the perioperative treatment of resectable locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The regimen combines three distinct therapeutic components: (1) trastuzumab rezetecan (SHR-A1811), a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) carrying a topoisomerase I inhibitor payload; (2) retlirafusp alfa (SHR-1701), a bifunctional fusion protein designed to simultaneously block the programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-beta) pathways; and (3) CAPOX, a standard chemotherapy doublet consisting of capecitabine and oxaliplatin. This combination is being evaluated in a randomized Phase II clinical trial sponsored by Tianjin Medical University Cancer Institute and Hospital to assess its safety, tolerability, and efficacy (measured by pathological complete response rate) in patients with resectable stage II-III gastric or GEJ adenocarcinoma.
- Other names
- SHR-A1811 + SHR-1701 + CAPOX
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)TS (Thymidylate synthase)
Beyond the preview
Go deeper on trastuzumab rezetecan + retlirafusp alfa + CAPOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab rezetecan + retlirafusp alfa + CAPOX.